EA201992324A1 - ANTI-TREM2 ANTIBODIES AND WAYS OF THEIR APPLICATION - Google Patents

ANTI-TREM2 ANTIBODIES AND WAYS OF THEIR APPLICATION

Info

Publication number
EA201992324A1
EA201992324A1 EA201992324A EA201992324A EA201992324A1 EA 201992324 A1 EA201992324 A1 EA 201992324A1 EA 201992324 A EA201992324 A EA 201992324A EA 201992324 A EA201992324 A EA 201992324A EA 201992324 A1 EA201992324 A1 EA 201992324A1
Authority
EA
Eurasian Patent Office
Prior art keywords
trem2
ways
application
trem2 antibodies
antibodies
Prior art date
Application number
EA201992324A
Other languages
Russian (ru)
Inventor
Тина Швабе
Эрик Браун
Филип Конг
Илария Тасси
Сын-Джу Ли
Арнон Розенталь
Роберт Пейчал
Нельс П. Нилсон
Original Assignee
ЭЛЕКТОР ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭЛЕКТОР ЭлЭлСи filed Critical ЭЛЕКТОР ЭлЭлСи
Priority claimed from PCT/US2018/045068 external-priority patent/WO2019028292A1/en
Publication of EA201992324A1 publication Critical patent/EA201992324A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Данное изобретение в общем относится к композициям, содержащим антитела, например моноклональные антитела, фрагменты антител и т.д., которые специфически связывают белок TREM2, например TREM2 млекопитающего или TREM2 человека, и использованию таких композиций для предотвращения, снижения риска или лечения нуждающегося в этом индивидуума.This invention generally relates to compositions containing antibodies, for example monoclonal antibodies, antibody fragments, etc. that specifically bind a TREM2 protein, for example, mammalian TREM2 or human TREM2, and the use of such compositions to prevent, reduce risk or treat a person in need thereof individual.

EA201992324A 2018-02-27 2018-08-02 ANTI-TREM2 ANTIBODIES AND WAYS OF THEIR APPLICATION EA201992324A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862636095P 2018-02-27 2018-02-27
PCT/US2018/045068 WO2019028292A1 (en) 2017-08-03 2018-08-02 Anti-trem2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
EA201992324A1 true EA201992324A1 (en) 2020-03-10

Family

ID=69942816

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992324A EA201992324A1 (en) 2018-02-27 2018-08-02 ANTI-TREM2 ANTIBODIES AND WAYS OF THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA201992324A1 (en)

Similar Documents

Publication Publication Date Title
EA202092825A1 (en) ANTI-SIRPA ANTIBODIES AND METHODS OF THEIR APPLICATION
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
EA201792221A1 (en) ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
EA201790342A1 (en) ANTIBODIES TO TREM2 AND METHODS OF THEIR APPLICATION
PH12019502463A1 (en) Anti-cd33 antibodies and methods of use thereof
EA202190235A1 (en) ANTIBODIES TO CD33 AND METHODS OF THEIR APPLICATION
EA201890145A1 (en) ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION
EA202190138A1 (en) ANTI-SIRP-BETA1 ANTIBODIES AND METHODS OF THEIR USE
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
EA202190183A1 (en) ANTIBODIES TO SIGLEC-5 AND METHODS OF THEIR APPLICATION
MX2022007231A (en) Anti-mertk antibodies and methods of use thereof.
CR20220078A (en) Anti-ms4a4a antibodies and methods of use thereof
MX2021015212A (en) Anti-sortilin antibodies for use in therapy.
MX2019009498A (en) Fgf21 mimetic antibodies and uses thereof.
EA202092595A1 (en) ANTIBODIES TO SIGLEC-7 AND METHODS OF THEIR APPLICATION
EA201992324A1 (en) ANTI-TREM2 ANTIBODIES AND WAYS OF THEIR APPLICATION
EA201992335A1 (en) ANTIBODIES AGAINST SORTILIN AND WAYS OF THEIR APPLICATION
EA201992319A1 (en) ANTI-CD33 ANTIBODIES AND WAYS OF THEIR APPLICATION
EA202092279A1 (en) ANTIBODIES TO MICA AND / OR MICB AND THEIR APPLICATION
AR122237A1 (en) ANTI-SORTILINA ANTIBODIES AND METHODS FOR THEIR USE
EA202091393A1 (en) ANTI-MCT1 ANTIBODIES AND THEIR APPLICATION